Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.79 CAD | +0.84% | +3.01% | +21.27% |
08/04 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
14/03 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.27% | 111M | |
+15.05% | 69.5B | |
-1.76% | 24.09B | |
+8.13% | 8.2B | |
-18.28% | 7.97B | |
-0.98% | 7.84B | |
+19.12% | 4.32B | |
0.00% | 4.19B | |
-3.02% | 3.89B | |
+23.97% | 3.62B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Says Vascepa is Now Reimbursed by Ontario's Provincial Drug Plan